Please assess the completion status of the following clinical trial:

Trial Title: Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female travellers ≥ 18 years of age.~  * General good health.~ * Written informed consent.~ * Ability to attend all visits scheduled in this study.~ * Travellers who have previously got a primary vaccination series of 2 or 3 doses of JE-MB and now receive a booster vaccination , either MB-JEV or IXIARO, at the travel clinic for their journey to Asia, OR~ * Travellers with no previous vaccination against JE who are given the primary vaccination series with IXIARO at a travel clinic prior to their journey to Asia.~Exclusion Criteria:~* - \< 18 years of age.~* Acute disease at the time of enrollment.~* Pregnancy or lactation.~* Known immunodeficiency or immune suppressive treatment.~* Any chronic illness that might interfere with the immune response; history of JE.~* Alcohol or drug abuse.~* Any clinically significant history of known or suspected anaphylaxis or hypersensitivity (based on the investigator's judgement).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- A) primary immunization with MB-JEV (Type: ACTIVE_COMPARATOR): Volunteers immunized with MB-JEV
- Primary and booster MBJEV vaccinations (Type: ACTIVE_COMPARATOR): Booster immunization with MB-JEV of vaccinees primed with MB-JEV
- C) primary immunizations with Ixiaro (Type: ACTIVE_COMPARATOR): Primary immunization with Ixiaro 2 dose
- S) Ixiaro booster to MBJEV primed (Type: ACTIVE_COMPARATOR): Actual study group:Booster immunization with Ixiaro to those primed previously with MB-JEV

Based on this trial design, predict the completion outcome and termination type (if applicable).